on behalf of the BELNEU Consortium, on behalf of the the EU EOD Consortium, No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients, Neurobiology of Aging (2018Aging ( ), doi: 10.1016Aging ( / j.neurobiolaging.2018 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

Baradaran-Heravi et al., Negative report
No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients
Yalda Baradaran-Heravi 1, 3 , Lubina Dillen 1, 3 , Hung Phuoc Nguyen 1, 3 , Sara Van Mossevelde 1, 3, 4 , Jonathan Subsequent genetic screening revealed six additional rare missense mutations affecting the LCD in three unrelated ALS and two ALS-FTD patients, all absent from controls, giving an overall mutation frequency of ~2% fALS and <0.5% sALS (Mackenzie et al., 2017) . Aiming to replicate the reported genetic association of TIA1 with ALS and ALS-FTD, we set up a genetic screen of TIA1 in a European case-control series of ALS-FTD spectrum patients, including also pure FTD patients.
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We sequenced the entire TIA1 coding region (exon 1-13) in a total of 1120 patients and 1039 
Results
We identified a total of five rare (MAF <1%) heterozygous missense variants, with only one variant (p.Met290Thr) absent from the control cohort (See Supplementary material Table S1 and Figure S1 ).
All five missense variants mapped to the conserved TIA1 LCD region (exon 11 -13).
The p. Met290Thr (rs116707801) was present in an Italian familial FTD patient (age at onset 64 years, age at death 67 years). In ExAC NFE, this variant is counted three times in 66732 alleles and has a CADD-score of 11.42. The second missense variant identified in patients, p.Val294Glu (rs769199100), was present in an isolated Italian ALS patient (onset age 39 years). It was reported only once in 66732 alleles of the ExAC NFE dataset and received a CADD-score of 20.9. However, we also observed the p.Val294Glu variant in one of our 1039 control individuals, also from Italian origin (age at inclusion 58 years). Furthermore, we detected a heterozygous missense variant p.Ala381Thr No further low frequency or common variants were detected.
Discussion
We 
